Stifel Nicolaus Raises Insulet (NASDAQ:PODD) Price Target to $293.00

Insulet (NASDAQ:PODD) had its price objective increased by Stifel Nicolaus from $245.00 to $293.00 in a report issued on Friday,Benzinga reports. The firm currently has a hold rating on the medical instruments supplier’s stock.

A number of other research firms have also issued reports on PODD. Wells Fargo & Company raised their price target on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday. Barclays increased their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Canaccord Genuity Group increased their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday. Morgan Stanley increased their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Finally, TD Cowen increased their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average target price of $289.06.

Insulet Trading Down 1.9 %

NASDAQ:PODD opened at $282.80 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a fifty day simple moving average of $272.98 and a 200-day simple moving average of $247.11. Insulet has a 12 month low of $160.19 and a 12 month high of $289.46. The company has a market capitalization of $19.84 billion, a P/E ratio of 48.84, a PEG ratio of 3.62 and a beta of 1.23.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, equities research analysts anticipate that Insulet will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently added to or reduced their stakes in PODD. Blue Trust Inc. boosted its stake in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC boosted its position in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Insulet during the fourth quarter worth about $36,000. Itau Unibanco Holding S.A. acquired a new position in shares of Insulet during the 4th quarter worth approximately $42,000. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 56 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.